1-(4-ethyl-phenyl)-2,2-dimethyl-propan-1-one | 93420-31-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(4-ethyl-phenyl)-2,2-dimethyl-propan-1-one
• 英文别名: 1-(4-Aethyl-phenyl)-2,2-dimethyl-propan-1-on；1-(4-ethylphenyl)-2,2-dimethylpropan-1-one
• CAS: 93420-31-6
• 化学式: C₁₃H₁₈O
• 分子量: 190.285
• InChiKey: UGURUYFRZZDXNJ-UHFFFAOYSA-N

物化性质

• 沸点：
  85 °C(Press: 0.2 Torr)
• 密度：
  0.935±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  乙基苯 、 三甲基乙酰氯 在 三氯化铝 作用下， 生成 1-叔丁基-4-乙基苯 、 1-(4-ethyl-phenyl)-2,2-dimethyl-propan-1-one
  参考文献：
  名称：

  415.芳族化合物与叔酸衍生物之间的反应。第二部分 叔酰氯对苯衍生物的酰化作用

  摘要：

  DOI：

  10.1039/jr9490001950

文献信息

• Benzoxazole Derivatives Having Inhibitory Activity Against Interleukin-6, Preparation Method Thereof, and Pharmaceutical Composition Containing the Same
  申请人：Park Choo Hea Young

  公开号：US20130090480A1

  公开（公告）日：2013-04-11

  The present invention relates to benzoxazole derivatives represented by the Formula 1, which has an inhibitory activity against interleukin-6 (IL-6), a method for preparation thereof, and a pharmaceutical composition containing the same. The compound represented by the Formula 1 according to the present invention has a superior inhibitory activity against interleukin-6, and therefore, can be practically applied for prevention and treatment of diseases caused by abnormal interleukin-6 activity.

  本发明涉及由公式1表示的苯并噁唑衍生物，其具有对白细胞介素-6（IL-6）的抑制活性，以及其制备方法和含有该化合物的药物组合物。根据本发明的公式1所表示的化合物具有优越的抑制白细胞介素-6的活性，因此，可以实际应用于预防和治疗由异常白细胞介素-6活性引起的疾病。
• HYDROGELS FOR THE CONTROLLED RELEASE OF BIOACTIVE MATERIALS
  申请人：LEHN Jean-Marie

  公开号：US20080057005A1

  公开（公告）日：2008-03-06

  The present invention relates to the formation of hydrogels based on guanosine hydrazide derivatives in the presence of cations. The hydrogels can be used as a carrier/delivery system for biologically active substances such as flavors, fragrances, insect attractants or repellents, bactericides, fungicides, pharmaceuticals or agrochemicals.

  本发明涉及在阳离子存在下基于鸟苷肼衍生物形成水凝胶。该水凝胶可以用作生物活性物质（如香料、香味、昆虫引诱剂或驱虫剂、杀菌剂、杀真菌剂、药物或农药）的载体/传递系统。
• Diphenyl Substituted Alkanes as Flap Inhibitors
  申请人：Chu Lin

  公开号：US20110190346A1

  公开（公告）日：2011-08-04

  The instant invention provides compounds of formula I which are 5-lipoxygenase activating protein inhibitors. Compounds of formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.

  本发明提供了公式I的化合物，它们是5-脂氧合酶激活蛋白抑制剂。公式I的化合物可用作抗动脉粥样硬化、抗哮喘、抗过敏、抗炎和细胞保护剂。
• NO- AND H2S- RELEASING COMPOUNDS
  申请人：Kashfi Khosrow

  公开号：US20140221316A1

  公开（公告）日：2014-08-07

  This disclosure relates to novel compounds containing an H 2 S releasing moiety and a nitric oxide (NO) releasing moiety covalently linked with a core (e.g., a salicylic acid moiety) and the use of such compounds in treating inflammatory diseases, including cancers. Therapeutic potency of these compounds is significantly higher than NSAIDs containing a H 2 S-releasing moiety alone (HS-NSAIDs) and NSAID containing a NO-releasing moiety alone (NO-NSAIDs). The compounds, in addition, exhibit reduced side effect, e.g., reduced stomach ulcers, upon administration.

  本公开涉及新型化合物，其包含一个释放H2S的基团和一个共价连接于核心（例如水杨酸基团）的释放一氧化氮（NO）的基团，并且这些化合物的用途是治疗炎症性疾病，包括癌症。这些化合物的治疗效力明显高于仅含有释放H2S的基团（HS-NSAIDs）和仅含有释放NO的基团（NO-NSAIDs）的非甾体类抗炎药（NSAIDs）。此外，这些化合物在治疗中表现出较少的副作用，例如减少胃溃疡。
• NSAIDs DERIVATIVES AND USES THEREOF
  申请人：THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK

  公开号：US20150376162A1

  公开（公告）日：2015-12-31

  The present invention discloses novel compounds derived from NSAIDs and pharmaceutically acceptable salts thereof. Other aspects of the invention relate to use of the NSAID derivatives in treating inflammatory diseases and pharmaceutical compositions thereof.

  本发明揭示了从非甾体抗炎药（NSAIDs）衍生出的新化合物及其药学上可接受的盐。本发明的其他方面涉及使用NSAID衍生物治疗炎症性疾病以及其制药组合物。